日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non-Small Cell Lung Cancer

基于深度学习的连续CT扫描预测免疫疗法治疗的非小细胞肺癌患者的生存期

Sako, Chiharu; Kurland, Brenda F; Schmidt, Taly G; He, Jing; De Groot, Marius; Patel, Arpan A; Owen, Dwight H; Amini, Arya; Curti, Brendan D; Kelly, Ronan J; Page, Ray D; Swalduz, Aurelie; Beregi, Jean-Paul; Chrusciel, Jan; Sanchez, Stephane; Weiss, Jakob; Liu, An; Gevaert, Olivier; Hart, Alma; Simon, George R; Parikh, Ravi B; van der Aart, Jasper; Jordan, Petr

Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers

突变类型、酪氨酸激酶在正常细胞中的功能以及酪氨酸激酶抑制剂在癌症中的活性

Vanacker, H; Cassier, P A; Dufresne, A; Pérol, M; Verlingue, Loic; Swalduz, A; Vinceneux, A; Attignon, V; Brahmi, M; Tredan, O; Tirode, F; Blay, J -Y

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO

在真实世界环境中,接受阿特珠单抗联合化疗治疗的广泛期小细胞肺癌患者的长期反应和生存情况:IFCT-1905 CLINATEZO

Falchero, Lionel; Amrane, Karim; Godbert, Benoît; Leterre, Bénédicte; Madelaine, Jeannick; Fournel, Pierre; Mascaux, Céline; Raimbourg, Judith; Schneider, Sophie; Swalduz, Aurélie; Veillon, Rémi; Langlais, Alexandra; Missy, Pascale; Morin, Franck; Westeel, Virginie; Girard, Nicolas

Feasibility and Preliminary Efficacy of Aerobic Acute Exercise Prior to Immunotherapy and Chemotherapy Infusion in Patients with Metastatic Non-Small Cell Lung Cancer: A Randomized Controlled Trial

有氧急性运动对转移性非小细胞肺癌患者免疫治疗和化疗输注的可行性和初步疗效:一项随机对照试验

Gouez, Manon; Pérol, Olivia; Pialoux, Vincent; Avrillon, Virginie; Boussageon, Maxime; Decroisette, Chantal; Delrieu, Lidia; El Hajj, Houssein; Fournier, Baptiste; Gille, Romane; His, Mathilde; Mastroianni, Bénédicte; Swalduz, Aurélie; Pérol, Maurice; Fervers, Béatrice

Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers

抗IL-6R抗体托珠单抗用于治疗实体瘤副肿瘤炎症综合征

Blay, J-Y; Brahmi, M; Dufresne, A; Swalduz, A; Avrillon, V; Assaad, S; Decroisette, C; Mastroianni, B; Dupont, M; Bourbotte-Salmon, F; Ray-Coquard, I; Meeus, P; Dutour, A; Castets, M; Perol, M; Heudel, P

COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer

COMPOSIT 研究:评估奥希替尼联合靶向疗法治疗 EGFR 突变型非小细胞肺癌

Mehlman, Camille; Swalduz, Aurelie; Monnet, Isabelle; Morin, Clara; Wislez, Marie; Guisier, Florian; Curcio, Hubert; Du Rusquec, Pauline; Cortot, Alexis B; Gounant, Valerie; Abbar, Baptiste; Duchemann, Boris; Giroux-Leprieur, Etienne; Pierret, Thomas; Quilot, Fleur-Marie; Cadranel, Jacques; Fallet, Vincent

Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients

深度学习揭示了与癌症患者疾病侵袭性相关的YAP1/TEAD活性组织学模式

Schmauch, Benoit; Cabeli, Vincent; Domingues, Omar Darwiche; Le Douget, Jean-Eudes; Hardy, Alexandra; Belbahri, Reda; Maussion, Charles; Romagnoni, Alberto; Eckstein, Markus; Fuchs, Florian; Swalduz, Aurélie; Lantuejoul, Sylvie; Crochet, Hugo; Ghiringhelli, François; Derangere, Valentin; Truntzer, Caroline; Pass, Harvey; Moreira, Andre L; Chiriboga, Luis; Zheng, Yuanning; Ozawa, Michael; Howitt, Brooke E; Gevaert, Olivier; Girard, Nicolas; Rexhepaj, Elton; Valtingojer, Iris; Debussche, Laurent; de Rinaldis, Emanuele; Nestle, Frank; Spanakis, Emmanuel; Fantin, Valeria R; Durand, Eric Y; Classe, Marion; Von Loga, Katharina; Pronier, Elodie; Cesaroni, Matteo

Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage

劳拉替尼一线治疗晚期ALK阳性非小细胞肺癌:一种高效的新标准疗法,但其疗效仍具有挑战性。

Wespiser, Mylène; Swalduz, Aurélie; Pérol, Maurice

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

恩曲替尼治疗 ROS1 阳性晚期非小细胞肺癌:BFAST II/III 期试验

Peters, Solange; Gadgeel, Shirish M; Mok, Tony; Nadal, Ernest; Kilickap, Saadettin; Swalduz, Aurélie; Cadranel, Jacques; Sugawara, Shunichi; Chiu, Chao-Hua; Yu, Chong-Jen; Moskovitz, Mor; Tanaka, Tomohiro; Nersesian, Rhea; Shagan, Sarah M; Maclennan, Margaret; Mathisen, Michael; Bhagawati-Prasad, Vijay; Diarra, Cheick; Assaf, Zoe June; Archer, Venice; Dziadziuszko, Rafal

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

NVL-655 是一种选择性、脑渗透性抑制剂,可抑制多种 ALK 突变癌蛋白,包括劳拉替尼耐药化合物突变

Jessica J Lin #, Joshua C Horan #, Anupong Tangpeerachaikul #, Aurélie Swalduz, Augusto Valdivia, Melissa L Johnson, Benjamin Besse, D Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E Ko